Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Lilly Endowment Inc. filed a Form 144 notice to sell 300,000 shares of Eli Lilly and Company common stock. The filing lists an aggregate market value of $258,858,000, with Fidelity Capital Markets as broker and an approximate sale date of 11/03/2025. The shares are listed on NYSE and NASDAQ.
Shares outstanding were 945,383,757; this is a baseline figure, not the amount being offered. In the past three months, the seller reported multiple open-market sales, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 301,342 shares on 10/31/2025 for $260,164,971.74.
Lilly Endowment, Inc. filed Amendment No. 43 to Schedule 13G reporting beneficial ownership of 95,492,993 shares of Eli Lilly (LLY) common stock, representing 10.1% of the class. The ownership is reported as of September 30, 2025, and the percentage is based on 946,456,759 shares outstanding as of August 4, 2025 per the issuer’s Form 10‑Q.
The Endowment has sole voting power and sole dispositive power over 95,492,993 shares, with no shared voting or dispositive power. The filer is an Indiana not‑for‑profit organization and private foundation.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of Eli Lilly (LLY) common stock. As of 09/30/2025, Vanguard reported 80,952,595 shares, representing 8.55% of the class. Vanguard is identified as an investment adviser and certified the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing details 0 shares with sole voting power and 4,843,238 shares with shared voting power. Vanguard reported 73,223,987 shares with sole dispositive power and 7,728,608 shares with shared dispositive power. The filing also notes that Vanguard’s clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
Eli Lilly (LLY) reported sharply higher Q3 results. Revenue rose to $17,600.8 million from $11,439.1 million a year ago, driven by cardiometabolic medicines. Net income increased to $5,582.5 million from $970.3 million, with diluted EPS of $6.21 versus $1.07.
Growth was led by Mounjaro ($6,515.1 million total) and Zepbound ($3,588.1 million), lifting total cardiometabolic health revenue to $13,177.9 million. Oncology contributed $2,407.6 million, and immunology $1,362.4 million. Operating cash flow for the nine months reached $13,588.4 million. Cash and equivalents were $9,791.9 million, while long‑term debt was $40,873.6 million. The company recognized $655.7 million of acquired IPR&D and $364.9 million of special charges in the quarter.
Lilly completed the Verve Therapeutics acquisition for $549.4 million net of cash, with a contingent value right of up to $300.0 million. Pre‑launch inventories were $952.3 million, primarily for orforglipron. As of September 30, $12.40 billion remained under the $15.00 billion share repurchase authorization. Shares outstanding were 945,383,757 as of October 27, 2025.
Eli Lilly and Company furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The information in Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104 for the cover page Inline XBRL. The document identifies Lilly’s listed securities, including common stock (LLY) on the NYSE.
Adverum Biotechnologies (ADVM) is the target of a planned tender offer by Eli Lilly and Company via its wholly owned subsidiary, Flying Tigers Acquisition Corporation, under an Agreement and Plan of Merger dated October 24, 2025.
The tender offer has not yet commenced. Upon commencement, Lilly and its subsidiary will file tender offer materials on Schedule TO, and Adverum will file a Schedule 14D-9 to provide its position. These documents will be available on the SEC’s website and at Lilly’s investor site, and mailed to stockholders at no charge.
The communication includes forward-looking statements noting uncertainties around closing, potential contingent consideration, and availability of financing under a promissory note. Completion of the acquisition is not guaranteed and remains subject to customary conditions.
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.
Eli Lilly (LLY) director Mary Lynne Hedley reported an acquisition of 12.259 shares of common stock on 10/20/2025 at $808.96 per share. The filing states the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following her separation from service.
After the transaction, beneficial ownership stood at 2,015.828 shares held directly and 98 shares held indirectly by trust.